Physician profile
Thomas Harbert
NPI 1629058060
$865.97
in general payments reported to CMS, 2019-2025
18 companies · $131 in 2025
The $131 reported for 2025 was less than what a typical Orthopaedic Surgery provider received nationally (typical 2025 total: $569).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $32.39 · 2020: $224 · 2021: $18.00 · 2023: $185 · 2024: $275 · 2025: $131.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $591.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $591.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $337.93 | 2020-2025 | Omega, Iconix, Flexible Guide Pin (Stryker Acl Versitomic) |
| Aimmune Therapeutics, INC. | $110.84 | 2024 | |
| Abbvie INC. | $70.58 | 2023-2025 | |
| Novo Nordisk INC | $45.44 | 2023-2024 | Rybelsus, Ozempic |
| Amgen INC. | $42.63 | 2023-2024 | Evenity, Prolia |
| Lexicon Pharmaceuticals, INC. | $36.44 | 2023-2024 | Inpefa |
| Zimmer Biomet Holdings, INC. | $32.39 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $27.28 | 2024 | Trintellix |
| Janssen Pharmaceuticals, INC | $23.62 | 2024 | Invega Sustenna |
| Pacira Pharmaceuticals Incorporated | $21.03 | 2025 | Exparel |
| Smith+Nephew, INC. | $18.00 | 2021 | |
| Sun Pharmaceutical Industries INC. | $16.72 | 2024 | |
| Boston Scientific Corporation | $16.02 | 2023 | Watchman Flx |
| Exact Sciences Corporation | $14.59 | 2024 | Cologuard Collection Kit |
| Lilly USA, LLC | $14.05 | 2023 | Mounjaro, Trulicity |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $12.96 | 2023 | Auvelity |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $12.79 | 2023 | Xifaxan |
| Depuy Synthes Sales INC. | $12.66 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Harbert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.